Intuitive Surgical's da Vinci robots hit 16M procedures with AI-driven growth

Intuitive Surgical continues to lead in robotic surgery, with its da Vinci systems now used in over 16 million procedures globally. The company's latest financial results show strong growth, as demand for its technology expands across 72 countries.

The firm is also pushing into new areas, including AI-driven improvements and cardiac procedures, while maintaining steady revenue from servicing and supplies.

Intuitive Surgical reported a 19% revenue increase in its fourth quarter, with procedures rising by 18% year over year. During this period, the company installed 532 da Vinci systems, reinforcing its market position.

The da Vinci 5 system recently gained approval for certain cardiac surgeries, broadening its medical applications. Meanwhile, the Ion system now features AI-enhanced navigation, helping doctors overcome challenges like CT-to-body divergence in lung biopsies.

While the company's stock remains a growth investment, its price has dropped compared to last year. Most of its revenue—around 75%—comes not from system sales but from ongoing servicing and supplies.

The Asia-Pacific region is driving much of the growth, particularly in oncology treatments. Analysts project a higher compound annual growth rate (CAGR) there than in other markets, though exact figures on global adoption remain unclear.

Intuitive Surgical's technology is now active in 72 countries, with over 11,000 da Vinci systems installed worldwide. The company's focus on AI and expanding medical uses suggests continued growth in robotic-assisted surgeries.

For investors, the stock offers long-term potential, though market fluctuations may influence short-term decisions. Healthcare costs in retirement, meanwhile, remain a major concern, with a 65-year-old in 2025 expected to spend an average of $172,500 on medical expenses.